Clinical Trial Update: Apixaban Drug Utilization Study In Stroke Prevention In Atrial Fibrillation (Spaf)

View source ↗

Summary

A Pfizer-sponsored drug utilization study (SPAF) on apixaban for stroke prevention in atrial fibrillation has completed with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation

Drugs mentioned

• Apixaban (apixaban)

Snippet

Sponsor: Pfizer | Conditions: Atrial Fibrillation | Status: COMPLETED | Results posted: 2019-04-19